Cetuximab and platinum-based chemoradio- or chemotherapy of patients with epidermal growth factor receptor expressing adenoid cystic carcinoma: A phase II trial

E. Hitre, B. Budai, Z. Takácsi-Nagy, G. Rubovszky, E. Tóth, É Remenár, C. Polgár, I. Láng

Research output: Contribution to journalArticle

32 Citations (Scopus)

Abstract

Background:Epidermal growth factor receptor (EGFR) is highly expressed in adenoid cystic carcinoma (ACC). The efficacy and toxicity of cetuximab with concomitant platinum-based chemoradio- or chemotherapy in patients with locally advanced or metastatic ACC, respectively, was evaluated.Methods:Eligible patients (9 with locally advanced tumour and 12 with metastases) had positive tumour EGFR expression. The cetuximab loading dose (400 mg m -2) was followed by 250 mg m -2 per week. Locally advanced tumours were irradiated (mean dose 65 Gy) and treated with concomitant cisplatin (75 mg m -2, intravenously). Patients with metastases received concomitant cisplatin and 5-fluorouracil (4 × 1000 mg m -2).Results:For patients with locally advanced disease (median follow-up: 52 months), the median progression-free survival (PFS) was 64 months and the 2-year overall survival (OS) rate was 100%. For patients with metastases (median follow-up: 72 months), the median PFS and OS were 13 and 24 months, respectively. In both groups the objective response rate was >40%. Skin rash, in-field dermatitis, mucositis and vomiting were the most frequent grade 3/4 adverse events.Conclusion:In this single-arm study, the efficacy of cetuximab plus chemoradio- or chemotherapy appeared favourable as compared with historical controls. All side effects were manageable and did not hamper the treatment.

Original languageEnglish
Pages (from-to)1117-1122
Number of pages6
JournalBritish Journal of Cancer
Volume109
Issue number5
DOIs
Publication statusPublished - Sep 2013

Fingerprint

Adenoid Cystic Carcinoma
Platinum
Epidermal Growth Factor Receptor
Drug Therapy
Neoplasm Metastasis
Cisplatin
Disease-Free Survival
Neoplasms
Mucositis
Dermatitis
Exanthema
Fluorouracil
Vomiting
Survival Rate
Cetuximab
Survival

Keywords

  • cetuximab; adenoid cystic carcinoma; radiotherapy; chemotherapy

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

@article{f92796b887844322ab9804b602bed312,
title = "Cetuximab and platinum-based chemoradio- or chemotherapy of patients with epidermal growth factor receptor expressing adenoid cystic carcinoma: A phase II trial",
abstract = "Background:Epidermal growth factor receptor (EGFR) is highly expressed in adenoid cystic carcinoma (ACC). The efficacy and toxicity of cetuximab with concomitant platinum-based chemoradio- or chemotherapy in patients with locally advanced or metastatic ACC, respectively, was evaluated.Methods:Eligible patients (9 with locally advanced tumour and 12 with metastases) had positive tumour EGFR expression. The cetuximab loading dose (400 mg m -2) was followed by 250 mg m -2 per week. Locally advanced tumours were irradiated (mean dose 65 Gy) and treated with concomitant cisplatin (75 mg m -2, intravenously). Patients with metastases received concomitant cisplatin and 5-fluorouracil (4 × 1000 mg m -2).Results:For patients with locally advanced disease (median follow-up: 52 months), the median progression-free survival (PFS) was 64 months and the 2-year overall survival (OS) rate was 100{\%}. For patients with metastases (median follow-up: 72 months), the median PFS and OS were 13 and 24 months, respectively. In both groups the objective response rate was >40{\%}. Skin rash, in-field dermatitis, mucositis and vomiting were the most frequent grade 3/4 adverse events.Conclusion:In this single-arm study, the efficacy of cetuximab plus chemoradio- or chemotherapy appeared favourable as compared with historical controls. All side effects were manageable and did not hamper the treatment.",
keywords = "cetuximab; adenoid cystic carcinoma; radiotherapy; chemotherapy",
author = "E. Hitre and B. Budai and Z. Tak{\'a}csi-Nagy and G. Rubovszky and E. T{\'o}th and {\'E} Remen{\'a}r and C. Polg{\'a}r and I. L{\'a}ng",
year = "2013",
month = "9",
doi = "10.1038/bjc.2013.468",
language = "English",
volume = "109",
pages = "1117--1122",
journal = "British Journal of Cancer",
issn = "0007-0920",
publisher = "Nature Publishing Group",
number = "5",

}

TY - JOUR

T1 - Cetuximab and platinum-based chemoradio- or chemotherapy of patients with epidermal growth factor receptor expressing adenoid cystic carcinoma

T2 - A phase II trial

AU - Hitre, E.

AU - Budai, B.

AU - Takácsi-Nagy, Z.

AU - Rubovszky, G.

AU - Tóth, E.

AU - Remenár, É

AU - Polgár, C.

AU - Láng, I.

PY - 2013/9

Y1 - 2013/9

N2 - Background:Epidermal growth factor receptor (EGFR) is highly expressed in adenoid cystic carcinoma (ACC). The efficacy and toxicity of cetuximab with concomitant platinum-based chemoradio- or chemotherapy in patients with locally advanced or metastatic ACC, respectively, was evaluated.Methods:Eligible patients (9 with locally advanced tumour and 12 with metastases) had positive tumour EGFR expression. The cetuximab loading dose (400 mg m -2) was followed by 250 mg m -2 per week. Locally advanced tumours were irradiated (mean dose 65 Gy) and treated with concomitant cisplatin (75 mg m -2, intravenously). Patients with metastases received concomitant cisplatin and 5-fluorouracil (4 × 1000 mg m -2).Results:For patients with locally advanced disease (median follow-up: 52 months), the median progression-free survival (PFS) was 64 months and the 2-year overall survival (OS) rate was 100%. For patients with metastases (median follow-up: 72 months), the median PFS and OS were 13 and 24 months, respectively. In both groups the objective response rate was >40%. Skin rash, in-field dermatitis, mucositis and vomiting were the most frequent grade 3/4 adverse events.Conclusion:In this single-arm study, the efficacy of cetuximab plus chemoradio- or chemotherapy appeared favourable as compared with historical controls. All side effects were manageable and did not hamper the treatment.

AB - Background:Epidermal growth factor receptor (EGFR) is highly expressed in adenoid cystic carcinoma (ACC). The efficacy and toxicity of cetuximab with concomitant platinum-based chemoradio- or chemotherapy in patients with locally advanced or metastatic ACC, respectively, was evaluated.Methods:Eligible patients (9 with locally advanced tumour and 12 with metastases) had positive tumour EGFR expression. The cetuximab loading dose (400 mg m -2) was followed by 250 mg m -2 per week. Locally advanced tumours were irradiated (mean dose 65 Gy) and treated with concomitant cisplatin (75 mg m -2, intravenously). Patients with metastases received concomitant cisplatin and 5-fluorouracil (4 × 1000 mg m -2).Results:For patients with locally advanced disease (median follow-up: 52 months), the median progression-free survival (PFS) was 64 months and the 2-year overall survival (OS) rate was 100%. For patients with metastases (median follow-up: 72 months), the median PFS and OS were 13 and 24 months, respectively. In both groups the objective response rate was >40%. Skin rash, in-field dermatitis, mucositis and vomiting were the most frequent grade 3/4 adverse events.Conclusion:In this single-arm study, the efficacy of cetuximab plus chemoradio- or chemotherapy appeared favourable as compared with historical controls. All side effects were manageable and did not hamper the treatment.

KW - cetuximab; adenoid cystic carcinoma; radiotherapy; chemotherapy

UR - http://www.scopus.com/inward/record.url?scp=84883741316&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84883741316&partnerID=8YFLogxK

U2 - 10.1038/bjc.2013.468

DO - 10.1038/bjc.2013.468

M3 - Article

C2 - 23942070

AN - SCOPUS:84883741316

VL - 109

SP - 1117

EP - 1122

JO - British Journal of Cancer

JF - British Journal of Cancer

SN - 0007-0920

IS - 5

ER -